Case study on phenylketonuria: a memic autism

  • K. Nikhila Department of Pharmacy Practice, SIMS College of Pharmacy, Mangaldas Nagar, Guntur, Andhra Pradesh, India
  • V. Sahithi Department of Pharmacy Practice, SIMS College of Pharmacy, Mangaldas Nagar, Guntur, Andhra Pradesh, India
  • V.Yaswanth Reddy Department of Pharmacy Practice, SIMS College of Pharmacy, Mangaldas Nagar, Guntur, Andhra Pradesh, India
  • G. Venkata Nagaraju Assistant Professor, Department of Pharmacy Practice, SIMS College of Pharmacy, Mangaldas Nagar, Guntur, Andhra Pradesh, India
    drnagaraju.gv@gmail.com
  • Sitty Manohar Babu Professor and Principal, SIMS College of Pharmacy, Mangaldas Nagar, Guntur, Andhra Pradesh, India

Abstract

Phenylketonuria (PKU) is a phenylalanine catabolism metabolic condition characterized by a decrease in the activity of the phenylalanine hydroxylase or Dihydro pteridine reductase enzyme. This inherited condition causes a build-up of phenylalanine in the bloodstream. Elevated phenylalanine levels in the blood can cause muscle rigidity, choreoathetosis, tremors, hyperreflexia, dermatitis, pale skin, and pseudo-scleroderma. The central nervous system deficiencies in PKU are caused by phenylalanine and phenyl pyruvic acid competing for dopamine, adrenaline, norepinephrine, and serotonin in the brain. Structural changes are caused by neurotransmitter inhibition and phenylalanine and phenyl pyruvic accumulations in the white matter of the posterior periventricular, frontal, and subcortical areas of the brain1. Greater myelin turnover decreased synaptogenesis, and reduced neuronal digenesis ensues from myelin deficit, resulting in cognitive development and mental retardation1. The patient in this case study is an 8-year-old boy who has been diagnosed with phenylketonuria. The patient’s parents had a history of consanguinity marriage. The patient has had seizures since he was nine months old. Speech and language delays, hearing loss, and tooth discoloration are all common symptoms. He had an MRI and a brain scan, as well as a blood amino acids test, which revealed that he has mild developmental delays. Mild to Moderate Autistic Features is Delayed.

Keywords: Phenylketonuria, phenylalanine levels, neurotransmitter inhibition, synaptogenesis

Downloads

Download data is not yet available.

References

1. Mechanisms Underlying Induced Pseudo-Scleroderma among Patients with Phenylketonuria Metabolic Disorder Article in Global Journal of Dermatology & Venereology · March 2021.
2. Specific Genetic Disorders and Autism: Clinical Contribution Towards their Identification David Cohen,1,7 Nade`ge Pichard,2 Sylvie Tordjman,2 Clarisse Baumann,3 Lydie Burglen,4 Elsa Excoffier,5 Gabriela Lazar,1 Philippe Mazet,1 Cle’ment Pinquier,1 Alain Verloes,3 and Delphine He´ron6.
3. International Journal of Health Sciences & Research (www.ijhsr.org) 308 Vol.4; Issue: 7; July 2014 International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Case Report Phenylketonuria with Autism Spectrum Disorders- A Case Study V. Suresh Kumar Head, Neonatal Screening Laboratory, Neopel Bioscience Pvt. Ltd, Chennai, Tamilnadu, India.
4. Risperidone or Aripiprazole Can Resolve Autism Core Signs And Symptoms in Young Children: Case Study Hamza A. Alsayouf 1,* , Haitham Talo 1, Marisa L. Biddappa 1 and Emily De Los Reyes 2.
5. van Wegberg AMJ, MacDonald A, Ahring K, et al. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J Rare Dis 2017; 12:162.
6. https://www.uptodate.com/contents/overview-of-phenylketonuria/abstract/6van Wegberg AMJ, MacDonald A, Ahring K, et al. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J Rare Dis 2017; 12:162.
7. Food and Drug Administration. Approval for Risperdal (Risperidone) in Treatment of the Irritability Associated with Autistic Disorder. 2006. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/020272Orig1s036,s041,02058 8Orig1s024,s028,s029,21444Orig1s008,s015.pdf (accessed on 18 December 2020).
8. Bristol Myers Squibb. U.S. Food and Drug Administration Approves ABILIFY® (Aripiprazole) for the Treatment Of Irritability Associated with Autistic Disorder in Pediatric Patients (Ages 6 to 17 Years). 2009. Available online:https://news.bms.com/news/details/2009/US-Food-and-Drug-Administration-Approves-ABILIFY-aripiprazole-for-the-Treatment-of-Irritability-Associated-with-Autistic-Disorder-in-Pediatric-Patients-Ages-6-to-17-Years/default.aspx
Statistics
545 Views | 420 Downloads
How to Cite
K, N., V, S., V, Y. R., G, V. N., & Sitty , M. B. (2022). Case study on phenylketonuria: a memic autism. Asian Journal of Hospital Pharmacy, 2(4), 65-68. https://doi.org/10.38022/ajhp.v2i4.54
Section
Case Studies

Most read articles by the same author(s)